{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.44334","value":"2.4449"},{"groupId":"OG001","spread":"1.81211","value":"2.2344"}]}],"title":"MMAE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00704","value":"0.0140"},{"groupId":"OG001","spread":"0.01393","value":"0.0418"}]}],"title":"C4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.01017","value":"0.0205"},{"groupId":"OG001","spread":"0.00980","value":"0.0294"}]}],"title":"C5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00428","value":"0.0121"},{"groupId":"OG001","spread":"0.00840","value":"0.0252"}]}],"title":"C7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.04328","value":"0.0622"},{"groupId":"OG001","spread":"0.04163","value":"0.0392"}]}],"title":"C8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00371","value":"0.0105"},{"comment":"None of the participants had data above LLQ and as per the predefined protocol results were to be summarized only for observations above LLQ, hence, data was not reported.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C13"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses.","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses and rifampicin, 600 mg, capsules, orally, once daily from Day 1 of treatment Cycle 0 through Day 21 of treatment cycle 3.","id":"OG001","title":"Brentuximab Vedotin + Rifampicin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who received brentuximab vedotin at 1.8 mg/kg throughout Cycles 1 to 3 and had sufficient dosing and PK data to reliably estimate PK parameters.","reportingStatus":"POSTED","timeFrame":"Cycle 3: 96 hour postdose","title":"Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose","type":"PRIMARY","unitOfMeasure":"ng/mL"}